Dizal Pharmaceutical (688192)
Overview
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and s
Employees1009
Market Cap$18.9B
Revenue$894.0M
Listed OnShanghai Stock Exchange
Ticker688192
CEODr. Zhang Xiaolin Ph.D.
HeadquartersShanghai